UltraFrailMM
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma: A Phase 2 Multicenter Study
What will happen during the trial?
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality. We hypothesize that a go-slow gentle approach to starting treatment in such patients, starting with just Isatuximab and dexamethasone with a gentle introduction to lenalidomide third cycle onwards, may improve treatment adherence and quality of life.
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 40 patients (estimated)
- Sponsors
- University of Utah
- Collaborators
- Sanofi
- Tags
- Monoclonal Antibody, CD38
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1970
- NCT Identifier
- NCT06517017
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.